Abstract
Introduction
Intestinal Cl Ϫ secretion, the primary transport event of secretory diarrhea (1) , requires the coordinated activity of specific membrane ion transporters and channels found in epithelial cells lining crypts of the small and large bowel (2, 3) . These socalled "undifferentiated Cl
Ϫ secreting" cells accumulate Cl Ϫ ions above their electrochemical potential through the activities of NaK2Cl cotransporters and Na/K ATPase pumps in the basolateral membrane. Secretion into the intestinal lumen occurs by passive diffusion of Cl Ϫ through activated channels in the apical cell membrane (4, 5) . Basolateral K ϩ channels recycle transported K ϩ ions out of the cell, and are necessary to maintain the inside-negative electrochemical membrane potential which favors ion secretion (6) (7) (8) (9) (10) . These membrane proteins function together to secrete Cl Ϫ . Blockade of any one of these ion transporters or channels will attenuate the Cl Ϫ secretory response.
Intestinal Cl Ϫ secretion is regulated by agonists which elicit cAMP-, cGMP-, or Ca 2 ϩ -mediated intracellular signals. The activity of apical membrane Cl Ϫ channels, including the cystic fibrosis transmembrane regulator (CFTR) (11) , depends primarily on ligand-receptor driven cAMP-or cGMP-signaling cascades. These intracellular second messengers also regulate in tandem the activities of basolateral NaK2Cl cotransporters (12) (13) (14) , and K ϩ channels (6) (7) (8) (9) (10) (15) (16) (17) . Both cyclic nucleotide and Ca 2 ϩ -mediated intracellular signals affect basolateral K ϩ efflux pathways in the intestine, and two pharmacologically distinct K ϩ conductances have been identified (18) . One K ϩ efflux pathway displays dependence on intracellular cAMP, and sensitivity to Ba 2 ϩ salts (8, 19) . The other pathway is activated by Ca 2 ϩ agonists (20, 21) , and displays little or no sensitivity to Ba 2 ϩ , tetraethylammonium (TEA), 4-aminopyridine, or apamin (7, 8, 22) .
Recently, a Ca 2 ϩ -dependent K ϩ channel in the human intestinal cell line T84 has been biophysically defined (21) . Single channel recordings have identified an inwardly rectifying K ϩ conductance of 14-32 pS. Channel activity was dependent on Ca 2 ϩ and inhibited by charybdotoxin (a component of scorpion venom) and tetraethylammonium (TEA), but not by Ba 2 ϩ , apamin, or 4-aminopyridine. In separate studies using the whole cell perforated patch technique, two distinct K ϩ currents were identified in T84 cells. One K ϩ conductance was sensitive to charybdotoxin and the other was not sensitive to the toxin (23) . The molecular identities of these K ϩ channels remain unknown.
Our interest in the use of imidazole antibiotics such as clotrimazole (CLT) 1 to inhibit Cl Ϫ secretory responses arises from studies on K ϩ transport in the human red cell (24) (25) (26) (27) . Recently, CLT was shown to inhibit Ca 2 ϩ -dependent K ϩ channels in rat thymocytes and human erythrocytes (24) (25) (26) (27) (28) . Ca 2 ϩ -dependent K ϩ channels in the human erythrocyte (also known as the Gardos pathway [29] ), and murine erythroleukemia cells (30) display inwardly rectifying unitary conductances of 14-40 pS that are sensitive to blockade by charybdotoxin.
These biophysical parameters share some resemblance to those identified for Ca 2 ϩ -dependent K ϩ channels in human intestinal T84 cells, and suggest that CLT may affect K ϩ conductances in enterocytes as it does in the red cell.
To test this idea, we utilized the human intestinal cell line, T84. T84 cells form confluent monolayers of well differentiated columnar epithelia that exhibit high transepithelial resistances, polarized apical and basolateral membranes, and cAMP-and Ca 2 ϩ -regulated Cl Ϫ secretory pathways analogous to those found in native intestinal tissue (3, 31, 32) . Our data show that CLT reversibly inhibits both cAMP-and Ca 2 ϩ -dependent Cl Ϫ secretion, and suggest that CLT acts directly on both Ba 2 ϩ -sensitive and charybdotoxin-sensitive K ϩ efflux pathways. These studies provide evidence that CLT and related compounds may have utility in the treatment of secretory diarrheas of diverse etiology. 2 Transwell inserts (Costar Corp., Cambridge, MA) coated with dilute rat collagen solution as previously described (33, 34) . Transepithelial resistances attained stable levels ( Ͼ 1,000 ohms/ cm 2 ) after 7 d. The development of high transepithelial resistances correlates with the formation of confluent monolayers with welldeveloped tight junctions as assessed by morphological analysis, and with the ability of monolayers to secrete Cl Ϫ (32) . Passages 77 to 91 were used in these studies.
Methods

Materials
Measurement of electrogenic Cl
. Confluent monolayers were transferred to HBSS at 37 Њ C. Serosal and mucosal reservoirs were interfaced with calomel and AgAgCl electrodes via 5% agar bridges made with Ringer's buffer. Transepithelial resistance was measured during 25 or 50 A current pulses using a dual voltage clamp device (University of Iowa, Iowa City, IA). I sc was calculated using Ohm's law as previously described (33, 34) . Previous studies have shown that secretagogue-activated changes in I sc represent almost entirely apical Cl Ϫ secretion (12) . Rb activities were determined by gamma or scintillation counting, and normalized to percent total uptake as previously described (35) .
86
Rb uptake studies. Confluent monolayers on 5-cm 2 Transwell inserts were preincubated for 30 min at 37ЊC in HBSS or HBSS containing CLT (33 M). Subsets of both control and CLT treated monolayers were then treated or not treated with bumetanide (10 M, for 12 min). All monolayers were then exposed to VIP (5 nM) basolaterally and shifted to HBSS containing 1 Ci/ml 86 Rb for 3 min at 37ЊC.
Rb uptake was terminated by washing the inserts in an icecold solution containing 100 mM MgCl 2 , and 10 mM Tris-Cl, pH 7.4. Monolayers were cut from their inserts, placed into scintillation vials, and counted using standard methods as above.
Fluorescence ratio imaging of intracellular free Ca 2ϩ ion concentration. T84 cells cultured at subconfluent density on collagencoated 5-cm 2 coverslips were incubated in growth media containing 2 M Fura-2-acetoxymethyl ester (Fura-2 AM; Molecular Probes, Eugene, OR) for 30 min at 37ЊC in humidified 5% CO 2 , then washed and mounted in a modified Leiden chamber in which the coverslip constituted the bottom. 1 ml of HBSS was added to the coverslip chamber on the stage of an inverted microscope (IMT-2; Olympus Corp., Lake Success, NY) equipped with a Dage-MTI CCD7 series video camera (Dage-MTI, Michigan City, IN).
The intracellular concentration of free calcium ([Ca 2ϩ ] i ) was measured in room air at room temperature by Fura-2 fluorescence ratio imaging using an Image-1 digital imaging system (Universal Imaging, West Chester, PA) equipped with GenIISys image intensifier (Dage- Figure 1 . Effect of CLT on the Cl Ϫ secretory response (I sc ) in T84 cells. Monolayers were pretreated with or without BaCl 2 (3 mM, n ϭ 7), charybdotoxin (100 M, n ϭ 4), or clotrimazole (33 M, n ϭ 7) for 30 min at 37ЊC, then stimulated basolaterally with VIP (5 M) or carbachol (CRB, 100 M). Peak I sc values (A/cm 2 , meanϮSEM) in the absence of inhibitors were 83Ϯ3 (VIP) and 50Ϯ8 (CRB). CLT inhibited the Cl Ϫ secretory response to both agonists. *Significant differences between treated and untreated control monolayers as determined by ANOVA, P ϭ 0.005-0.0001. MTI), a Pinnacle REO-650 optical disk drive (Pinnicle Micro, Inc., Irvine, CA), color video monitor and printer, as described previously (36) . Isolated cells and cells at the periphery of cell clusters accumulated Fura-2 to higher levels than cells in the center of clusters. Therefore, intracellular free [Ca 2ϩ ] i was monitored in the cells at the edges of clusters. All individual cells and cell clusters demonstrating Fura-2 uptake were included in data analysis. Exposure of cells to 0.25% Pluronic F-127 (Molecular Probes) during Fura-2 loading did not increase Fura-2 accumulation in cells in the center or at the edges of the cell clusters.
Fura-2 fluorescence images were monitored at an emission wavelength of 510 nM, with alternating excitation wavelengths of 340 and 380 nm. Images and ratio data sets were collected at intervals ranging between 6 and 120 s, and stored to optical disk for later image replay and data processing. In vitro calibration of the Fura-2 free acid fluorescence ratio to the concentration of free Ca 2ϩ was performed in vitro by the method of Grynkewicz et al. (36) ] i in T84 cells are based on in vitro calibration of the Fura-2 fluorescence ratio. However, in situ fluorescence ratio calibration was successfully performed at nominal [Ca 2ϩ ]i values of 100 and 200 nM. The ratios measured in situ at these two concentrations did not differ significantly from those determined by the in vitro calibration procedure at the same values of free [Ca 2ϩ ] (P Ͼ 0.2). Statistics. IC 50 's for inhibition of Cl Ϫ secretion were derived from nonlinear fits of dose response data (n ϭ 7 and 9 independent experiments for VIP and carbachol, respectively) to Michaelis-Menten kinetics using Deltagraph Pro 3.5 (Deltapoint, Monterey, CA). Origins were constrained to 100% maximal response in the absence of CLT. Tests of significance where indicated were based on ANOVA using Statview 512ϩ (BrainPower, Calabasas, CA). -insensitive. In agreement with these studies, we found that Ba 2ϩ (3 mM) inhibited by 80Ϯ0.4% (meanϮSEM, n ϭ 3) the peak short-circuit current elicited by the cAMP-dependent agonist vasoactive intestinal peptide (VIP, 5 nM), but minimally inhibited (by 16.5Ϯ10.7%, meanϮSEM, n ϭ 4) the Cl Ϫ secretory response elicited by the Ca 2ϩ -dependent agonist carbachol (100 M) (Fig. 1, bars on left) . Charybdotoxin (100 nM) inhibited 81Ϯ1% (meanϮSEM, n ϭ 4) of the Cl Ϫ secretory response elicited by carbachol, but only minimally attenuated (by 10Ϯ2%, meanϮSEM, n ϭ 4) Cl Ϫ secretion elicited by treatment with the cAMP agonist, VIP (Fig. 1, middle bars) . Unlike either Ba 2ϩ or charybdotoxin, preincubation with the imidazole antibiotic clotrimazole (CLT, 33 M) strongly inhibited the Cl Ϫ secretory responses elicited by both carbachol and VIP, reducing peak I sc 's by 84Ϯ3.5% and 74Ϯ8.9% respectively (meanϮSEM, n ϭ 4) (Fig. 1, bars on right) . Fig. 2 shows the dose dependence of inhibition of Cl Ϫ secretion by CLT. These inhibitory effects of CLT on Cl Ϫ secretion were maximal after 30 min incubation (data not shown). Fig. 2 , A and C show the time courses of the Cl Ϫ secretory response elicited by carbachol or VIP in the absence or presence of increasing concentrations of CLT. To examine possible effects of CLT on the synergy between cAMP-and Ca 2ϩ -mediated agonists, monolayers initially stimulated with VIP (Fig. 2  C) were allowed to reach steady-state levels of secretion and then additionally exposed to carbachol (100 M). CLT was slightly more effective in inhibiting the secretory response to carbachol (Fig. 2 B) than to cAMP (Fig. 2 D) with IC 50 values of 3.5Ϯ1.0 and 6.1Ϯ0.9 M, respectively (meanϮSE, n ϭ 9 or 7). This was most clearly seen when the effects of CLT on cAMP- (Fig. 2 E, VIP alone) and Ca 2ϩ -dependent secretory pathways (Fig. 2 E, VIP ϩ carbachol) were examined on the same monolayers. In low doses ‫ف(‬ 10 Ϫ7 M or less), CLT increased slightly (by 5-10%) the Cl Ϫ secretory responses to either agonist, but this finding was variable. CLT inhibited effectively the secretory response to cholera toxin (20 nM, a cAMP-dependent agonist) and E. coli heat-stabile toxin (100 nM, a cGMP-agonist) (IC 50 values of 10 M and 15 M, respectively) (Fig. 3) . Inhibition of Cl Ϫ secretion by CLT (10 M) was fully reversible (96Ϯ2%, n ϭ 4) after 60 min recovery in the presence of 0.01 mg/ml bovine serum albumin.
Results
Clotrimazole reversibly inhibits Cl
Among the imidazole antibiotics, CLT was the most potent inhibitor of cAMP and Ca 2ϩ elicited Cl Ϫ secretion (Table I) . Ketoconazole, econazole, and miconazole were effective but less potent. Among the drugs tested, only CLT was more potent in blocking carbachol-induced secretion than VIP-induced secretion. Each of the other compounds tested were either more effective inhibitors of the secretory response to cAMP agonists, or had no detectable effect on the secretory response to Ca 2ϩ agonists. A stable metabolite of CLT lacking the imidazole ring, 2-chlorophenyl-bis-phenyl methanol, was nearly as effective as CLT (Table I) . Metronidazole was not effective in blocking either cAMP-or Ca 2ϩ -mediated Cl Ϫ secretory processes.
Clotrimazole acts at distal steps in the cAMP-and Ca 2ϩ -dependent signal transduction pathways. To determine the site of CLT action, we examined the effect of CLT pretreatment on monolayers stimulated with agonists that initiate Cl Ϫ secretion at sequential steps in the cAMP-signaling cascade (Fig. 4 A) . Synergy represents the increase in short circuit current (I sc ) elicited by carbachol (100 M) applied to monolayers initially stimulated with VIP (5 nM) and allowed to reach steady state levels of secretion.
T84 monolayers were preincubated in HBSS in the presence or absence of CLT (33 M) and then stimulated with either 5 M VIP (which activates adenylate cyclase through heterotrimeric GTPase-linked cell surface receptors), 10 M forskolin (which activates adenylate cyclase directly), or 3 mM 8Br-cAMP (a direct stimulator of protein kinase A). CLT (10 M) inhibited the secretory response to each of these agonists (Fig.  4 A) . These data provide evidence that CLT acts at a step distal to the activation of protein kinase A. Ca Fig. 4 B illustrates that CLT (33 M) inhibited by 80-90% the Cl Ϫ secretory response to each of these reagents. These data suggest that CLT acts at steps in the secretory response distal to the release of intracellular Ca 2ϩ stores.
Clotrimazole does not inhibit apical membrane anion conductance or basolateral NaK2Cl cotransporters. Inhibition of electrogenic Cl
Ϫ secretion might occur by blockade of apical membrane Cl Ϫ channels, or blockade of basolaterally situated NaK2Cl cotransporters, K ϩ channels, or NaK ATPase pumps. To determine if CLT affected ion conductance through apical membrane Cl Ϫ channels, we examined the time course of 125 I efflux from T84 monolayers pretreated in the presence or absence of CLT (35) . I efflux from monolayers treated or not treated with CLT were indistinguishable (0.0637 vs 0.0645% uptake/minute, n ϭ 2 independent experiments with 2 independent monolayers in each experiment). CLT had similar lack of effect on 125 I efflux stimulated by thapsigargin (data not shown, n ϭ 2). These data do not support any effect of CLT on apical Cl Ϫ channels. We next tested the effect of CLT on basolateral NaK2Cl cotransporters, as assessed by bumetanide-sensitive 86 Rb uptake (13, 14) (Fig. 5 B) . CLT treatment reduced the total amount of 86 Rb uptake by 53.6Ϯ5.8% (meanϮSEM, n ϭ 6), but had no effect on the fractional component that was bumetanide-sensitive (88Ϯ3.2 vs 75.2Ϯ12.7% total uptake, meanϮ SEM). Taken together, these data suggest that CLT does not affect Cl Ϫ secretion in T84 cells via inhibition of either apical membrane Cl Ϫ channels or basolateral membrane NaK2Cl cotransporters.
Clotrimazole inhibits K ϩ efflux in T84 cells. We examined whether CLT might inhibit K ϩ permeability in T84 cells as it does in the human red cell (26) . K ϩ channel activity was esti- Rb efflux (35) . Fig. 6 shows that CLT significantly inhibited the rate of 86 Rb efflux after treatment with the cAMP agonist VIP (5 M, Fig. 6 A) . The rate constant for VIP-stimulated 86 Rb efflux was reduced by 87% in monolayers treated with CLT (0.0062 vs 0.0465% uptake/ minute, n ϭ 3 independent experiments with 2 independent monolayers in each experiment). CLT inhibited to a similar degree 86 Rb efflux from monolayers stimulated with thapsigargin (Fig. 6 B, rate constants 0.011 vs 0.048% uptake/minute, n ϭ 3 independent experiments with two independent monolayers in each experiment). These data strongly suggest that CLT can inhibit Cl Ϫ secretion by blockade of K ϩ transport through both Ba 2ϩ -sensitive and charybdotoxin-sensitive channels. In further support of this hypothesis, we found that the inhibitory effect of CLT was more rapid in onset when CLT was applied to basolateral than to apical cell surfaces. Fig. 7 shows tests of sidedness of inhibition of VIP-stimulated Cl Ϫ secretion by CLT. As seen in Fig. 7 , A and B, most rapid inhibition was achieved by incubation with CLT on both sides of the monolayer. However, basolateral application alone was almost as effective. Fig. 7 C shows that the apparent potency of inhibition of CLT at a fixed time point was greater when applied basolaterally than apically. This preferential action of CLT at the basolateral surface of the cell is consistent with the hypothesis that its principal targets are basolateral K ϩ channels. It is likely that the attenuated rate of inhibition by apically applied clotrimazole represents diffusion through the monolayer due to the lipid solubility of the compound.
Clotrimazole elicits intracellular Ca 2ϩ transients in T84 cells but does not elicit a Cl
Ϫ secretory response. Recently, CLT was found to have direct effects on Ca 2ϩ signaling in Swiss 3T3 fibroblasts (46) . Treatment with CLT (10 M), elicited a rapid increase in intracellular Ca 2ϩ via release from intracellular stores, but the normally ensuing influx of extracellular Ca ] i response to subsequent addition of thapsigargin (46) . These studies prompted us to examine the effect of CLT on Ca 2ϩ signaling in T84 cells. Fig. 8 shows that CLT (10 M) elicited a brisk Ca 2ϩ transient in T84 cells (Fig. 8, open circles) , increasing intracellular Ca 2ϩ more than threefold above resting values (125Ϯ6 vs peak responses of 353Ϯ29 nM, meanϮSEM, n ϭ 18 cell clusters). The initial Ca 2ϩ transient elicited by CLT was followed by a significant and prolonged elevation in intracellular Ca 2ϩ (168 nMϮ8, meanϮSEM, n ϭ 15 cell clusters). The elevation in levels of intracellular Ca 2ϩ elicited by CLT was similar in magnitude and kinetics to that elicited by the muscarinic agonist carbachol (Fig. 8 insert) . CLT did not deplete intracellular Ca 2ϩ stores in T84 cells, in so far as subsequent stimulation with thapsigargin ( Fig. 8 C) or carbachol (data not shown) produced a Ca 2ϩ transient that was only marginally decreased in amplitude from that observed in cells not treated with CLT (CLT pretreated ϭ 96Ϯ17 vs thapsigargin ϭ 150Ϯ29 nM [Ca 2ϩ ] i , meanϮSEM, n ϭ 13 and 11 cell clusters. This small difference approached but did not reach statistical significance, P ϭ 0.06, ANOVA). Thus, CLT did not inhibit Cl Ϫ secretion elicited by carbachol or thapsigargin via inhibiton of the intracellular Ca 2ϩ signal generated by either agonist. These results contrast with the ability of CLT to deplete nearly completely the intracellular Ca 2ϩ stores of Swiss 3T3 fibroblasts (46) . Although CLT (10 M) elicited an intracellular Ca 2ϩ transient in T84 cells grown on glass (Fig. 8 A) , CLT did not elicit a corresponding Cl Ϫ secretory response from T84 monolayers grown on permeable supports and studied in parallel (Fig. 8 B,  open circles) . CLT clearly retained its bioactivity in this assay, as demonstrated by its inhibition of the Cl Ϫ secretory response elicited by thapsigargin (Fig. 8 D) .
Discussion
The results of this study show that the imidazole antibiotic CLT inhibits the Cl Ϫ secretory response of human intestinal T84 cells to both cAMP-and Ca 2ϩ -dependent agonists. Inhibition occurs at micrometer concentrations, and is fully reversible. CLT acts at distal steps in cAMP-and Ca 2ϩ -dependent signaling cascades, likely by direct inhibition of basolateral K ϩ channels. Neither apical Cl Ϫ conductance nor basolateral NaK2Cl cotransport appear to be affected.
Two lines of evidence support the view that CLT directly blocks basolateral K ϩ channels. First, two pharmacologically distinct K ϩ channels have been identified in intestinal T84 cells (6-9, 15, 16, 47) , and CLT appears to inhibit both as evidenced by a nearly fivefold reduction of 86 Rb efflux elicited by VIP or by carbachol. The observation that CLT acts at steps distal to the generation of intracellular Ca 2ϩ or cAMP, and inhibits the secretory response more efficiently when applied to basolateral cell surfaces is consistent with this proposed mechanism of CLT action. Recently, the 4-sulfonylaminochromanol, 293B, was found to attenuate Cl Ϫ secretory responses in isolated rabbit colon by inhibition of basolateral K ϩ channels (48) . In contrast to CLT, however, the activity of this compound was restricted to inhibition of cAMP-induced secretion. Secretory responses to Ca 2ϩ -agonists were unaffected. Secondly, CLT competitively displaces 125 I-bound charybdotoxin from red cells with ID 50 equivalent to that for blockade of A23187 activated 86 Rb efflux. These data suggest that CLT inhibits K ϩ conductance in erythrocytes by binding to the external surface of the Gardos channel (26) . Though inhibition by CLT of Cl Ϫ secretion (I sc ) in T84 cells is almost 100-fold less potent than inhibition of the Gardos channel, the Ca 2ϩ -dependent K ϩ channel of the red cell and T84 cells share some biophysical and pharmacological characteristics, including inward rectification, unitary conductance (21, 49) , inhibition by charybdotoxin, and insensitivity to Ba 2ϩ . CLT has also been shown to inhibit Ca 2ϩ -sensitive K ϩ conductances in rat thymocytes and Ehrlich ascites tumor cells (27) . Based on these data and that from the present study, we propose that CLT may act directly on both charybdotoxin-and Ba ever, Venglarik et al. (35) Clotrimazole is in current therapeutic use as a topical antifungal and is used in oral and vaginal preparations for mucosal candidiasis. Clotrimazole has been tested in humans as a systemic treatment of several conditions including rheumatoid arthritis (54, 55), severe esophageal (56) , and systemic chronic mucocutaneous candidiasis (57, 58) , and sickle cell disease (24, 26, 60) . In the most recent study, oral doses of 20 mg CLT/kg per day over 4-12-wk courses yielded plasma concentrations of 2.8-12.5 M (CLT and active metabolites) (60) with mild or no toxicity (55, 60) . These serum levels approximate or exceed the IC 50 's for inhibition of secretagogue-activated Cl Ϫ secretion in T84 cells.
A stable metabolite of CLT lacking the imidazole ring (2-chlorophenyl-bis-phenyl methanol) was also found to be effective at inhibiting Cl Ϫ secretory responses in T84 cells with nearly equal potency. These data show that the imidazole ring is not required for inhibitory activity in T84 cells. Adverse effects associated with clotrimazole are dose dependent. Reversible increases in hepatic transaminases and adrenal steroid levels (61) have been reported in humans and animals. These effects are thought to result from interactions between the imidazole ring and cytochrome P-450 enzymes (24, 62, 63) . Thus, metabolites of CLT or related compounds having the triphenyl structure but lacking the imidazole ring may display similar or greater efficacy in vivo with less toxicity. Moreover, the ability of compounds like 2-chlorophenyl-bis-phenyl methanol to inhibit Cl Ϫ secretion in T84 cells shows that inhibition of P450 enzymes is not required for the inhibition of K ϩ channels by CLT. In summary, these studies show that in the human intestinal cell line T84, the imidazole antibiotic clotrimazole attenuates the Cl Ϫ secretory response elicited by either cAMP-or Ca 2ϩ -dependent agonists. Cl Ϫ secretion elicited by E. coli heatlabile toxin (assessed using cholera toxin) or heat-stable toxin (STa) was completely inhibited by CLT. These bacterial enterotoxins are primarily responsible for the acute secretory diarrhea encountered by 30-70% of travelers to nonindustrialized regions of the world (64). E. coli enterotoxins also cause neonatal diarrhea (scours) of newborn farm animals. CLT appears to dissociate intracellular cAMP and Ca 2ϩ signals from Cl Ϫ secretion by inhibiting basolateral membrane K ϩ channels. Previous studies with oral clotrimazole have already shown in humans that plasma levels of 3.3 M or greater are achievable after a single oral dose of 1 gram (24, 60) . Such levels would be sufficient for inhibition of the intestinal secretory response as assessed in our in vitro system. Moreover, CLT is metabolized to active compounds of (likely) even lower toxicity. Thus we propose that oral clotrimazole and drugs of related structure may have utility in the treatment of acute and chronic secretory diarrheas of diverse etiologies.
